| 106817 |
aging
|
|
decreases_quantity of
|
Melatonin
|
in the ventricular CSF in elderly controls; to one-fifth
|
| 106819 |
Melatonin
|
|
decreases_activity of
|
aging
|
chronic melatonin treatment slows the functional decline in the aging brain
|
| 106821 |
Melatonin
|
|
decreases_activity of
|
Amyloid beta peptide (25-35)
|
in neuroblastoma cell cultures and human platelets; concerning Abeta25‚Äď35-induced circadian alterations and Abeta-induced oxidative stress, lipid peroxidation, cellular death and DNA damage
|
| 106822 |
Melatonin
|
|
decreases_activity of
|
cognitive impairment
|
in APP + presenilin 1 (PS1) double-transgenic mouse model of AD
|
| 106823 |
Melatonin
|
|
decreases_quantity of
|
Amyloid beta peptide
|
both in vivo and in vitro
|
| 106824 |
Melatonin
|
|
decreases_activity of
|
behavioral deficits
|
concerning behavioral deficits associated with apoptosis and cholinergic system dysfunction
|
| 106826 |
Melatonin
|
|
decreases_activity of
|
APOE (isoform E4)
|
via reversing the profibrillogenic activity of ApoE4 and neutralizing its neurotoxic combination with Abeta
|
| 106829 |
Melatonin
|
|
decreases_activity of
|
ACHE
|
melatonin reduced Abeta-induced AChE activity
|
| 106833 |
Melatonin
|
|
increases_activity of
|
insulin receptor signaling pathway
|
via restoring insulin/insulin receptor mechanisms, resulting in the inhibition of GSK-3beta and less Abeta accumulation and reduced tau hyperphosphorylation
|
| 106834 |
Melatonin
|
|
increases_activity of
|
PLC
|
acting through its MT2 receptor
|
| 106835 |
Melatonin
|
|
increases_activity of
|
Resveratrol
|
potentiating the neuroprotective properties of resveratrol against beta-amyloid-induced neurodegeneration by modulating 5'AMP-activated protein kinase (AMPK) pathway
|
| 106836 |
APOE (isoform E4)
|
|
decreases_quantity of
|
Melatonin
|
in the ventricular CSF of APOE4/APOE4 type patients
|
| 106852 |
Melatonin
|
|
decreases_activity of
|
circadian alteration
|
in neuroblastoma cell cultures and human platelets; circadian alteration induced by Abeta (25‚Äď35)
|
| 106853 |
Melatonin
|
|
decreases_activity of
|
response to oxidative stress
|
in neuroblastoma cell cultures and human platelets; oxidative stress induced by Abeta
|
| 106854 |
Melatonin
|
|
decreases_activity of
|
lipid peroxidation
|
in neuroblastoma cell cultures and human platelets; lipid peroxidation induced by Abeta
|
| 106855 |
Melatonin
|
|
decreases_activity of
|
apoptotic process
|
in neuroblastoma cell cultures and human platelets; cellular death induced by Abeta
|
| 106856 |
Melatonin
|
|
decreases_activity of
|
cellular response to DNA damage stimulus
|
in neuroblastoma cell cultures and human platelets; DNA damage induced by Abeta
|
| 106857 |
Melatonin
|
|
decreases_quantity of
|
amyloid beta deposits
|
both in vivo and in vitro ; melatonin prevents Abeta aggregation via direct interaction
|
| 106858 |
Melatonin
|
|
interacts (colocalizes) with
|
Amyloid beta peptide
|
both in vivo and in vitro ; melatonin prevents Abeta aggregation via direct interaction
|
| 106859 |
Melatonin
|
|
decreases_activity of
|
Abeta pathology
|
|
| 106860 |
Melatonin
|
|
increases_activity of
|
increased survival rate
|
in transgenic mouse models
|
| 106862 |
Melatonin
|
|
decreases_activity of
|
CASP3
|
|
| 106863 |
Melatonin
|
|
decreases_activity of
|
acetylcholine catabolic process
|
melatonin prevented acetylcholine degradation
|
| 106894 |
Melatonin
|
|
decreases_activity of
|
inflammatory response
|
melatonin possesses anti-inflammatory properties
|
| 106895 |
Melatonin
|
|
decreases_quantity of
|
Proinflammatory cytokine
|
by inhibiting NFkappaB, melatonin suppresses the production of proinflammatory cytokines
|
| 106896 |
Melatonin
|
|
decreases_activity of
|
NF-kappaB complex
|
by inhibiting NFkappaB, melatonin suppresses the production of proinflammatory cytokines
|
| 106897 |
Melatonin
|
|
decreases_activity of
|
NF-kappaB signaling
|
by inhibiting NFkappaB
|
| 106901 |
Melatonin
|
|
decreases_quantity of
|
IL1B
|
in transgenic mouse models; concerning Abeta-induced secretion of IL-1beta
|
| 106904 |
Melatonin
|
|
decreases_quantity of
|
IL6
|
in transgenic mouse models; concerning Abeta-induced secretion of IL-6
|
| 106905 |
Melatonin
|
|
increases_quantity of
|
BCL2
|
in AD transgenic mice and in ischemic brains; via preventing Abeta-induced depletion of bcl-2
|
| 106908 |
Melatonin
|
|
increases_activity of
|
PI3K/AKT signaling
|
melatonin increases PI3-K/Akt signaling activity, resulting in the inhibition of GSK-3beta and less Abeta accumulation and reduced tau hyperphosphorylation
|
| 106909 |
Melatonin
|
|
decreases_activity of
|
GSK3B
|
via restoring insulin/insulin receptor mechanisms and increasing PI3-K/Akt signaling activity
|
| 106910 |
Melatonin
|
|
decreases_quantity of
|
amyloid beta deposits
|
via restoring insulin/insulin receptor mechanisms and increasing PI3-K/Akt signaling activity
|
| 106911 |
Melatonin
|
|
decreases_phosphorylation of
|
MAPT
|
via restoring insulin/insulin receptor mechanisms and increasing PI3-K/Akt signaling activity
|
| 106912 |
Melatonin
|
|
decreases_quantity of
|
MAPT-hpyerphos
|
via restoring insulin/insulin receptor mechanisms and increasing PI3-K/Akt signaling activity
|
| 106917 |
Melatonin
|
|
increases_expression of
|
BCL2
|
in AD transgenic mice and in ischemic brains; via preventing Abeta-induced depletion of bcl-2
|
| 106918 |
Melatonin
|
|
decreases transport of
|
NCF1
|
from the cytosol to the plasma membrane; impairing the Abeta-induced assembly of phagocytic oxidase (PHOX) by inhibiting the translocation of the p47phox
|
| 106919 |
Melatonin
|
|
decreases transport of
|
NCF2
|
from the cytosol to the plasma membrane; impairing the Abeta-induced assembly of phagocytic oxidase (PHOX) by inhibiting the translocation of the p47phox
|
| 106922 |
Melatonin
|
|
increases_activity of
|
MTNR1A
|
in neural stem cells and in the adult brain
|
| 106923 |
Melatonin
|
|
increases_activity of
|
MTNR1B
|
in neural stem cells and in the adult brain
|
| 106924 |
Melatonin
|
|
increases_activity of
|
Protein kinase C
|
via diacylglycerol
|
| 106928 |
Melatonin
|
|
increases_phosphorylation of
|
FOXO1
|
|
| 106929 |
Melatonin
|
|
decreases_activity of
|
neurodegeneration
|
via inhibiting Abeta-induced cascade of neurodegenerative processes
|
| 106930 |
Melatonin
|
|
increases_quantity of
|
FOXO1-phos
|
|
| 106931 |
Melatonin
|
|
increases_activity of
|
circadian rhythm
|
Melatonin synchronizes circadian rhythms
|
| 106932 |
Melatonin
|
|
increases_activity of
|
extended life span
|
|
| 106933 |
Melatonin
|
|
increases_expression of
|
SIRT1
|
|
| 106935 |
Melatonin
|
|
decreases_quantity of
|
Free radical
|
via scavenging highly toxic free radicals
|
| 106936 |
aging
|
|
decreases_quantity of
|
Melatonin
|
|
| 106938 |
Melatonin
|
|
increases_activity of
|
AKT1
|
reactivating IGF1, thereby reducing insulin resistance and Abeta accumulation
|
| 106941 |
Melatonin
|
|
decreases_activity of
|
intestinal cholesterol absorption
|
|
| 106942 |
Melatonin
|
|
affects_activity of
|
NMDA receptor complex
|
possibly by redox modulation
|
| 106943 |
Melatonin
|
|
increases_activity of
|
mitochondrial protection
|
by preventing cardiolipin oxidation, avoiding MPTP opening and restoring Ca2+ balance
|
| 106973 |
Melatonin
|
|
decreases_expression of
|
pro-oxidant enzyme
|
by transcriptionally regulating nuclear factor (erythroid-derived 2)-like 2 (Nrf2)
|
| 106974 |
Melatonin
|
|
increases_expression of
|
Antioxidant enzyme
|
by transcriptionally regulating nuclear factor (erythroid-derived 2)-like 2 (Nrf2)
|
| 106975 |
Melatonin
|
|
increases_activity of
|
antioxidant effect
|
via upregulating antioxidant enzymes by transcriptionally regulating nuclear factor (erythroid-derived 2)-like 2 (Nrf2)
|
| 106976 |
Melatonin
|
|
affects_expression of
|
NFE2L2
|
hereby downregulating pro-oxidant enzymes and upregulating antioxidant enzymes and protecting against increased oxidative damage in the brain
|
| 106977 |
Melatonin
|
|
decreases_activity of
|
transition metal
|
via chelating
|
| 106978 |
Melatonin
|
|
decreases_activity of
|
insulin resistance
|
the age-related melatonin decline induces insulin resistance
|
| 106982 |
Melatonin
|
|
decreases_activity of
|
impaired glucose tolerance
|
the age-related melatonin decline induces glucose intolerance
|
| 106983 |
Melatonin
|
|
decreases_activity of
|
abnormal sleep pattern
|
the age-related melatonin decline induces sleep disturbance
|
| 106984 |
Melatonin
|
|
decreases_activity of
|
metabolic circadian disorganization
|
the age-related melatonin decline induces metabolic circadian disorganization
|
| 106987 |
Melatonin
|
|
decreases_quantity of
|
Hydroxyl radical
|
via chelating transition metals
|
| 106990 |
Melatonin
|
|
decreases_activity of
|
lipid peroxidation
|
|
| 106991 |
Melatonin
|
|
affects_quantity of
|
Ca2+
|
concerning intracellular free Ca2+; by directly binding to calmodulin, thereby decreasing the activity and autophosphorylation of CAMK II and activating PKC
|
| 106992 |
Melatonin
|
|
decreases_activity of
|
cardiolipin oxidation
|
thereby increasing mitochondrial protection
|
| 106993 |
Melatonin
|
|
decreases_activity of
|
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
|
thereby increasing mitochondrial protection via avoiding MPTP opening
|
| 106994 |
Melatonin
|
|
increases_activity of
|
calcium ion homeostasis
|
thereby increasing mitochondrial protection via avoiding MPTP opening
|
| 154965 |
Melatonin
|
|
increases_activity of
|
decreased ACHE activity
|
melatonin reduced Abeta-induced AChE activity
|
AlzNet-DB